BioMarin Pharmaceutical (NASDAQ:BMRN) closed Tuesday's losing trading session at $25.99. In the past year, the stock has hit a 52-week low of $17.70 and 52-week high of $28.42. BioMarin Pharmaceutical stock has been showing support around $25.16 and resistance in the $27.46 range. Technical indicators for the stock are Neutral. For a hedged play on this stock, look at the Jul '11 $25.00 covered call for a net debit in the $23.34 area. That is also the break-even stock price for this trade. This covered call has a duration of 143 days, provides 10.20% downside protection and an assigned return rate of 7.11% for an annualized return rate of 18.15% (for comparison purposes only). BioMarin Pharmaceutical does not pay dividends at this time.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac... -
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma... -
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th... -
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after... -
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y... -
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ... -
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment